C-QTELautologous regenerative cell therapy, adipose-derived regenerative cells, orthopedics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This is a longitudinal follow-up study of the RC-002 study, in which up to 246 subjects assigned to two randomization arms will be enrolled: an adipose-derived regenerative cell (ADRC) injection arm (ADRC treatment arm) and the SOC corticosteroid injection arm (active control arm). All subjects will be randomly assigned to ADRC treatment or active control arms in a 2:1 ratio and will be followed up for 6 months. The goal of the RC-004 study is to enroll all patients that were enrolled and treated in RC-002 and follow for 3 years.
Extension Study of Protocol RC-001- Safety and Efficacy of Adult Adipose-Derived Stem Cell Injection into Partial Thickness Rotator Cuff Tears. Purpose is to investigate the Long- term safety and efficacy of autologous stem cells in patients with partial thickness rotator cuff tears versus a steroid treatment.
The purpose of this investigation is to evaluate the safety and superior effectiveness in functional improvement in patients with partial-thickness rotator cuff tears (PTRCTs) after the administration of a single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear compared to the administration of a single corticosteroid injection into the associated subacromial space.
What if a cutting edge technology saved your life? And then what if you got to be part of a startup company that is working on similar technology to save others' lives? Karen Momper, of Theratome Bio is living that story. This week, Micheal Coleman, PhD, and Karen tell the story of Theratorm Bio and the exciting platform they are working on. Learn about how Theratome Bio is developing a portfolio of products derived from adult stem cell secretions. The future includes exciting potential therapies like stroke treatment and organ preservation during transport. Learn Michael's and Karen's inspiring stories. Resources in this episode: Indiana Center for Biomedical Innovation TheratomeBio.com Theratome Bio on LinkedIn Theratome Bio on Facebook About Michael Coleman, PhD: Michael brings a wealth of research and new drug development experience to Theratome Bio. He directed multidisciplinary teams at GeneMedicine and Valentis in Houston, Texas, prior to accepti
This is a prospective, randomized, active controlled, single site safety and efficacy study in subjects suffering from chronic lumber back pain due to facet joint osteoarthritis comparing a single ADRC injection generated with the Transpose® RT system into the facet joint.
This is a prospective, randomized, double-blinded, active controlled, single site safety and efficacy study in subjects suffering from chronic wrist osteoarthritis comparing a single ADRC injection generated with the Transpose® RT system into the wrist.
Unite to Cure: Fourth International Vatican Conference: Friday, April 27, 2018 The Pharmacy of the Future – Cells Not Pills Moderator: Sanjay Gupta, MD 1. Eckhard U. Alt, MD, PhD, Todd and Linda Broin Distinguished Professor and Chair, Sanford Health at University of South Dakota; Professor, Technische University and Tulane University and Founder and Chairman of the Board, Isar Klinikum in Munich and InGeneron Inc. in Houston 2. Jason Hurd, MD, Sanford Orthopedics and Sports Medicine Mark Allen Lundeen, MD, Trustee, Sanford Health and Sanford Orthopedics and Sports Medicine 3. Jack Nicklaus, Record 18-time Major Championship Winner and World Golf Hall of Fame Member
This is a prospective, randomized, single-site, safety and efficacy study of subjects with chronic venous stasis ulcers. Patients will fall into two categories: treatment arm (24 subjects) and non-treatment or control arm (12 subjects). The treatment group will undergo a small liposuction procedure and receive placement of autologous cell therapy (stromal vascular fraction or SVF) injected around the rim of venous stasis wound (subcutaneously)following standard wound debridement, with saturation of collagen dressing material with standard over-dressing. Control (non-treatment) subjects will receive debridement and dressing changes as per standard of care without SVF.
This is a prospective, randomized, multi-site, safety and efficacy study in subjects with rotator cuff injuries. Patients will fall into two categories: treatment group (12 subjects) and non-treatment or control group (six subjects). The treatment group will undergo a small liposuction procedure and receive rotator cuff repair treatment with an ultrasound-guided injection of 5cc adipose-derived stem cells (ADSCs) into the point of injury. The control group will receive a 5cc cortisone injection into the point of injury
Cellular Horizons: How Science , Technology, Information and Communication Will Impact Society, Vatican City, April 28-30, 2016. Day 3: Cellular Frontiers: Research, Regulation and Funding, April 30, 2016. Eckhard U. Alt, MD, PhD, Todd and Linda Broin Distinguished Professor and Chair, Sanford Research, Sanford Health; Professor, Technische University and Tulane University; and Founder and Chairman of the Board at Isar Klinikum in Munich and InGeneron, Inc., in Houston, discusses where adult stem cells can be collected and how they can be used to repair our bodies. http://celltherapyconference2016.com
≠XHIBITOR LIST - 51 - Southwest Veterinary Symposium EN English Deutsch Français Español Português Italiano Român Nederlands Latina Dansk Svenska Norsk Magyar Bahasa Indonesia Türkçe Suomi Latvian Lithuanian český русский български العربية Unknown Login to YUMPU News Login to YUMPU Publishing TRY ADFREE Discover products News Publishing Magazines Create ePaper Login to YUMPU News Login to YUMPU Publishing × Attention! Your ePaper is waiting for publication! By publishing your document, the content will be optimally indexed by Google via AI and sorted into the right category for over 500
Tradex | Companies Login Register Contact Tradex Services Tradex Exhibitions Full-service partner for your next trade fair Tradex Network Networking as the basis for successful work Virtual Fair Personalised, digital 3D exhibition stands Shows Event-Liste All upcoming and past events Floorplans Interactive maps for the event News Companies Market Place Exhibitor Catalogue Your all-in-one guide for the next trade show. Open user menu Login Registrieren Contact Tradex Companies 11 Companies found Filter by Country Germany, (9) Switzerland, (2) Filter by Category Compression Devices, (1) Implants … ssion Devices, (1) Implants & Prosthetics, (1) Asia Health 2017 - Singapore Apply Clear Filters Tradex Services GmbH Münsing, Germany ANITA Dr. Helbig GmbH Brannenburg, Germany Transatlantic Handelsgesellschaft Stolpe & Co. mbH Neu-Anspach, Germany adamus Group Aachen, Germany Elma Schmidbauer GmbH Singen, Germany Endo-Flex GmbH Voerde, Germany InGeneron Inc. München, Germany Ortho-Medical GmbH Duerbheim, Germany Ortho Select GmbH Wurmlingen, Germany Regen Lab Le Mont
%PDF-1.7 %���� 5 0 obj > stream H�\��n� �� > stream H�|PoLw�k�6r����� �A3(EbP�2 [�j@C �=������2��!2���������f F�����p|Y��e#Y��^�]��|? ��J �m�*Z�fMyI W�qU */++K�JT银 ��GQ�.���� �d�*�JQeg'J[(HA���? � D�]����Dc_|H�=>��#w )��E��# �~dx�M~1��Uc� ���4\�t�W��WeQPJ�5� =�F>a;aI�y��` +���2H�n"HL�� �}�?08����K� m ��h؇�rx D)�����A��L�ޚ�a 68���R N11�d�-�_��C��c�yvt���إtu��֎#;�ؙДvq� ���g�p =N� ,�bp,��5z�od{��94v�����67����,�kׇ�)&��5�=�|l���� � i簟��������Gm��Hť���@ �����:���;t6t��#n��+�8��Wm{���7� �4V�>���K����=X2���������E_�D�� ��A;|4�=]�o����٘��.� ���� … �� �'���yx�����%��d�6���e!E�g?��=iI��\�p��)��1T8����(Q�v���75&@ȟܠ�kFū�rFP�q��ACۑF�� ������3 �|u �CX��h'㔐���X�q1�p�@mI���#�� �&}�����ߵ��c�6�2��.8� :{�Μ�G���) 40HÒ��A� �vǃ Ѐ��.$�=�s2"A �a�� �D����(Z��l�J33�%TY��� @� qo!(8t�5���v�-�.4� @״�� �#� ����%�4Z�gp�G>�� 2� o�����i��mJif��j�����d+q����@ A��'?���(( [aZ��P 7lA�=�A���� vʳ�� �� �8=��D�úPQ�-*���F*09�A���l�i�}�$+�s�h�(���g�߇1���>��(i0U.Č|eXa����-`� 8n h*R�I� 8�� … dc8d1da339 xmp.id:a5982bcb-91b0-403c-aa31-9a677d13a49d proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign CC 14.0 (Macintosh) / 2021-03-10T13:20:56-05:00 xmp.iid:0f6fe662-13cb-4597-b0bb-1be1b683b3e3 xmp.did:31853772-2099-4351-8826-dbdc8d1da339 xmp.did:31853772-2099-4351-8826-dbdc8d1da339 default application/pdf Adobe PDF Library 15.0 False endstream endobj 111 0 obj > endobj 114 0 obj > stream H�\�ۊ�0����� �=8Q(�x/����� ��X/|���_\�@�/d&��L��o … 98 adobe:docid:indd:cd25e841-4978-11e4-8c20-e23c854c24ad default converted from application/x-indesign to application/pdf Adobe InDesign CC 13.1 (Macintosh) / 2021-01-19T16:27:04-05:00 application/pdf Adobe PDF Library 15.0 False endstream endobj 149 0 obj > endobj 152 0 obj > stream H�\��j�0D���9&� ��h%%�C�P� KkWPKB����U�BZ؝yҬ$.�K�]��=�Q��M4�%BO���\�:���T3�($��:g�Z?�4��,�9�8 > endobj 154 0 obj > stream H� > stream H�2425R0P020Q�5456S040� �r�(�s�� ,L`*�R��M � C … c11da6325ef xmp.did:481e6fa8-336f-0c42-aa5c-5789f36c5c27 default converted from application/x-indesign to application/pdf Adobe InDesign 16.1 (Windows) / 2021-03-18T10:05:07-04:00 application/pdf Adobe PDF Library 15.0 False endstream endobj 338 0 obj > endobj 341 0 obj > stream H�\��n�0E���Y6�B�$B�H"��C��b)R1�! ��3�(�j ���ǏkGU}�m?C��G�� ]o��
About InGeneron | InGeneron LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Skip … t of the body where you find them and concentrate those cells, extract them and apply them to the site where you need them. The mission of Interneuron is to translate basic knowledge of stem cell research into clinical application for the benefit of the patient. Johannes Hahn 2y Report this comment Very impressive and vital technology in an era of population aging. Wishing you all continued success in its development in the quest to change patients’ lifes! Hope you are well.
eCTD Submissions Process for US FDA, EU & Canada | Workshop by Ex-FDA Official By using this site you agree to our use of cookies. Please refer to our privacy policy for more information. Close Explore Webinars Webinars All Webinars All FDA Regulated Industry Accounting & Taxation Banking & Financial Services Clinical Research Corporate Governance Drugs & Chemicals (Pharma) EH&S, Green Compliance Food & Dietry Supplements GXP Medical Devices GXP Pharmaceutical Healthcare HR Compliance Life Sciences Medical Devices Microsoft Office OSHA Compliance Quality Management Risk Management SOX C … She was responsible for the filing of the first gene therapy Biologics License Application (BLA) to the FDA and filed two gene therapy Marketing Authorization Applications (MAA) to the EMA. At Valentis, Inc. (formerly Gene Medicine Inc.), Ms. French led the Analytical Sciences core teams in support of the company’s cardiovascular, oncology and PEG protein programs. With long tenure at Lark Technologies, as Vice President of Operations, she managed the DNA sequencing, library
Stem Cell Therapy at InGeneron - Case Study Careers Investor Relations Order Here English French German English French German Japanese Japonaise japanisch XM Octopus™ Products Instruments NucleoCounter ® Instruments NucleoCounter ® NC-3000™ NucleoCounter ® NC-250™ NucleoCounter ® NC-202™ NucleoCounter ® NC-200™ NucleoCounter ® SP-100™ XcytoMatic ® Instruments XcytoMatic ® 40 XcytoMatic ® 30 NucleoCounter ® NC-203™ Ovizio iLine F PRO Analyzer Legacy Instruments Product review Consumables Cassettes Slides Reagents Lysis Accessories Cables Labware Power supply Software Services Service Plans GMP- … ; Winemaking Cultured Meat Preferred Partners Tecan Support Technical Documents Application Notes Certificates Package Inserts Product Notification Safety Data Sheets Tech Notes User Guides Product Support Contact Us FAQs Free Demo Request Quote Request Support Knowledge Our Science Our Cassette Technology Cell Assays Product Brochures Whitepapers and Ebooks Our Customers Case studies Publications Publications Review Scientific Posters Resources Journal Webinars & Talks … electing the NC-200™ as our automatic cell counter saved us time during the FDA application as well as during training of the staff at the clinical sites. The quality of the device and the excellent customer service that ChemoMetec provides has been a key factor in the successful initiation of our clinical program.” Glenn Winnier, PhD, Chief Scientific Officer Learn more about InGeneron . agsdix-c259284-contact Free Demo agsdix-c259284-edit Get a Quote agsdix-c259284-contact
%PDF-1.5 %���� 16746 0 obj > endobj 16765 0 obj >/Filter/FlateDecode/ID[ ]/Index[16746 36]/Info 16745 0 R/Length 101/Prev 3344967/Root 16747 0 R/Size 16782/Type/XRef/W[1 3 1]>>stream h�bbd```b`` "g�H��`�p)5 D2�����@$����"��$#X\� �n���b@�hF�i�@�#��O�P��� �~0�'V endstream endobj startxref 0 %%EOF 16781 0 obj >stream h��V}Lg�wW�H�w�z@ETVT0��D� ��ܡ8`Bl �.�ǕlRu`���ԥ*�-��[�$��9�¬(�F�q&~��Dg����2���%y��������= @� ����ؒ�I ͌��8'�a��S,zE�GFA�+ O �SE�IM�(,ؘv2���Of������۹&�T�8�$�i��%X���+�'����N|���M������j��+؛��B�����啻b=�� fT*�R�N9�>�U�����7d�~K��~1K �,Jn� … bb85e71295a xmp.did:3d23a2ac-b1fd-4b43-a79a-2a3e97ad6d2c default converted from application/x-indesign to application/pdf Adobe InDesign CC 2014 (Macintosh) / 2015-10-05T11:46:25-04:00 application/pdf Adobe PDF Library 11.0 False endstream endobj 6 0 obj >stream H��W]o��}_i�b^v���@�%3RbO2��g�8w��c�6Z ^��x��C�c>�8��(���}NU�*����z�� � �~[�6��p�-�?}-�\j��m�Wt���dʍ�sp���i�BMp�dQ"��T j��s� ��p��]Xw��i���WI��Dq�� v� ��"0M�z�e�X�>HУğR ��1����$^p���mb� k F�a��U��)b� … bb85e71295a xmp.did:3d23a2ac-b1fd-4b43-a79a-2a3e97ad6d2c default converted from application/x-indesign to application/pdf Adobe InDesign CC 2014 (Macintosh) / 2015-10-05T11:46:25-04:00 application/pdf Adobe PDF Library 11.0 False endstream endobj 12 0 obj >stream H��W]o��}_i�b^v���@�%3RbO2��g�8w��c�6Z ^��x��C�c>�8��(���}NU�*����z�� � �~[�6��p�-�?}-�\j��m�Wt���dʍ�sp���i�BMp�dQ"��T j��s� ��p��]Xw��i���WI��Dq�� v� ��"0M�z�e�X�>HУğR ��1����$^p���mb� k F�a��U��)b … '�qV~ ٖ��R�� ��d��;Tw��4i����]�l������ endstream endobj 137 0 obj >stream application/pdf REVOLVE_2016_IFATs_Ad Karleta Peggott /RM Visual Assets/Marketing Collateral/Tradeshow collateral 2016-10-14T13:25:41-04:00 2016-10-14T13:25:44-04:00 2016-10-14T13:25:51 Adobe InDesign CC 2014 (Windows) uuid:bea60d8f-a2fd-4551-94f4-6508b8479bb1 xmp.did:6772f9b7-dd3c-40a6-bc8e-e69e797b6ba4 xmp.id:a144f8bf-4405-b74a-9db1-3c82a5fd6704 proof:pdf xmp.iid:704f9ead-ac39-47c1-8b8e-b51a6a61 … c94aca36ad2 xmp.did:6772f9b7-dd3c-40a6-bc8e-e69e797b6ba4 default converted from application/x-indesign to application/pdf Adobe InDesign CC 2014 (Windows) / 2016-10-14T13:25:41-04:00 Adobe PDF Library 11.0 False Revolve, Ad, IFats REVOLVE_2016_IFATs_Ad_58572_5.indd endstream endobj 138 0 obj >stream H��V]o�6} �� �/0I�D}v�NҠub�F�%�*K�D��~�.%
Our Pharma Partnering team is excited to be attending the virtual JP Morgan Health Care Conference this week. Meet one of our #GenentechChangemakers, Nnamdi Ihuegbu, in the video below and learn how he is fulfilling his passion of helping patients and positively impacting society through his role here. Help us build successful collaborations by joining our Pharma Partnering team: https://bit.ly/3r7Rf9w. #JPMHC22 #JPM22 | Genentech Jobs
Isolation of Neonatal Rat Cardiomyocytes --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Publications Home / Publication / Improved Method for Isolation of Neonatal Rat Cardiomyocytes with Increased Yield of C-Kit+ Cardiac Progenitor Cells February 2, 2015 Category: Basic Science Jennifer Rutering,1 Matthias Ilmer,1 Alejandro Re … at Collagenase 2 alone leads to very high yields of cardiomyocytes, whereas the application of Matrase™ enzyme blend increases the relative yield of c-Kit+ CPCs to up to 35%. Cardiomyocytes and CPCs isolated with this protocol may constitute an important cell source for investigating heart disease as well as cell based therapeutic approaches. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, … don Healing Clinical Feb 26, 2019 Improved guided bone regeneration by combined application of unmodified, fresh autologous adipose derived regenerative cells and plasma rich in growth factors: A first-in-human case report and literature review Pre-clinical Nov 5, 2018 Effects of local application of adipose-derived stromal vascular fraction on tendon-bone healing after rotator cuff tear in rabbits Pre-clinical Jan 5, 2018 Magnetic resonance imaging and biomechanical analysis
Imprint - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Imprint Imprint with Medical disclaimers. Home / Imprint Legal Notice with Medical Disclaimers Information pursuant to Section 5 TMG and Section 55 RStV: InGeneron GmbH Sonnenstraße 24-26 80331 Munich Germany Phone: +49 (0) 89 149 903 1927 Email: [email  … oducts are intended exclusively for use by qualified medical professionals. The application of medical devices, particularly the Transpose Ultra System, is permitted only by trained medical personnel and in accordance with regulatory approvals. Information regarding regenerative cell therapy is based on study results that are not universally applicable and must be evaluated individually for each patient. MDR Compliance: The use of the Transpose Ultra System is exclusively wit
InGeneron Inc. Services Tradex Exhibitions Full-service partner for your next trade fair Tradex Network Networking as the basis for successful work Virtual Fair Personalised, digital 3D exhibition stands Shows Event-Liste All upcoming and past events Floorplans Interactive maps for the event News Companies Market Place Exhibitor Catalogue Your all-in-one guide for the next trade show. Login Register Contact Tradex Services Tradex Exhibitions Tradex Network Virtual Fair Shows Event-Liste Floorplans News Companies Market Place Exhibitor Catalogue Login Register Contact Tradex InGeneron Inc. InGe
InGeneron Publishes Landmark Study in Tendon Regeneration --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us News Home / News / InGeneron Publishes Landmark Study Demonstrating Structural Tendon Regeneration with Autologous Cell Therapy System July 23, 2025 Category: Press Releases InGeneron Publishes Landmark Study Demonstratin
Ingeneron, Inc. | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Ingeneron, Inc. InGeneron is a clinical-stage biotechnology company dedicated to developing evidence-based, minimally invasive regenerative cell therapies for orthopedic conditions. With over 20 years of research, the company focuses on unlocking the healing potential of patients' own regenerative cells processed at the point of care for same-day treatment. Their innovative platform, Transpose Ultra®, isolates regenerative cells from adipose tissue using p … ls from adipose tissue at the point of care for same-day autologous therapeutic application. Services Point-of-care autologous regenerative cell therapy (investigational) On-site clinical service model enabling mini-liposuction adipose harvest, bedside processing of autologous regenerative cells using an automated closed-system platform, and image-guided re-administration within a single outpatient visit for investigational treatment in orthopedic and wound-healing indication
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
InGeneron raises $20m in Series D for regenerative stem cell therapies - Drug Delivery Business Skip to primary navigation Skip to main content Skip to primary sidebar Skip to footer Advertise Subscribe Drug Delivery Business Search this website Clinical Trials Research & Development Drug-Device Combinations FDA Pharmaceuticals Policy Reports Diabetes Technology Innovations Special Report Continuous Glucose Monitoring (CGM) Market Report InGeneron raises $20m in Series D for regenerative stem cell therapies March 6, 2017 By Sarah Faulkner InGeneron said today that healthcare provider Sanfo … apies available to clinical practice and to establish a leading position in the application of adipose-derived regenerative cells.” Sanford started enrolling patients in the company’s safety and efficacy clinical trial earlier this year, evaluating InGeneron’s adipose-derived stem cell injections. The injections are made up of a mixture of cells and nutrients isolated from a patient’s own body as a treatment for partial-thickness rotator cuff tears, ac
InGeneron Announces EU Certification Under MDR --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us News Home / News / InGeneron, Inc. Announces EU Quality Management System Certificate Under MDR Regulation (EU) 2017/745 for Medical Devices February 4, 2026 Category: Press Releases InGeneron, Inc. Announces EU Quality Management S
Patient Safety Action Network Community | Phony Money Makers Prey On Gullible Patients
Broad Applicability of Cell Therapy --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us News Home / News / New Study Reports Broad Applicability of InGeneron’s Regenerative Cell Therapy System Across Patient Groups January 6, 2023 Category: Press Releases New Study Reports Broad Applicability of InGeneron’s Regenerative Cell Ther
You need to enable JavaScript to run this app. Loading...
Stem cell research at Sanford Health set for next phase - World Stem Cell Summit About WSCS About Us 2026 Regenerative Medicine Essentials Course Past WSCS Speakers WSCS Public Day (2023) Effective Patient Advocacy Symposium Intersection of RegMed & Healthspan Regenerative Medicine & the Commercial Space Economy Hot Topics in 2023 at World Stem Cell Summit Partners/Sponsors Partners/Sponsors Sponsorship Opportunities Upcoming Events News & Media News and Opinions WSCS 2023 Photos WSCS Video Contact Us Select Page Stem cell research at Sanford Health set for next phase by admin | … ropist Denny Sanford received the RMF Stem Cell Action “Leadership” Award, at the 2013 World Stem Cell Summit in San Diego. It was his vision and focused philanthropy that brought forth Sanford Health, now one of the largest health systems in the United States, dedicated to the integrated delivery of health care, genomic medicine, regenerative medicine, senior care and services, global clinics, research and affordable insurance. Headquartered in Sioux Falls, South … tries with 100 exhibitors. Phacilitate Leaders World was honored to receive the award for ‘Best Global Conference at the 2018 AEO Awards in London. This year, Phacilitate and RMF expect to attract 2,000 attendees, 150 exhibitors and 300 speakers representing every major stakeholder group. For the latest additions to the agenda and world-renowned speakers, visit http://www.phacilitate-leaders-world.com/ . To download a brochure with pricing and agenda information at a glance,
InGeneron & German Accelerator Collab --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us News Home / News / InGeneron Establishes Presence in Cambridge, MA and Initiates Collaboration with German Accelerator Life Sciences December 5, 2016 Category: News InGeneron Establishes Presence in Cambridge, MA and Initiates Collaborat
InGeneron Appoints Angelo Moesslang as Chief Executive Officer | FirstWord HEALTHTECH You need to enable JavaScript to run this app. Loading...
InGeneron Completes Strategic Financing from Sanford Health to Advance Regenerative Cell Therapies | FirstWord HEALTHTECH You need to enable JavaScript to run this app. Loading...
Sanford Health backs Ingeneron's point-of-care cell therapy with $20M + | Bioworld | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health Ch
InGeneron Brings Aboard a New CEO - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Release … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business InGeneron Brings Aboard a New CEO October 4, 2017 | 2 min read Twitter LinkedIn Facebook Email Print InGeneron Appoints Angelo Moesslang as Chief Executive Officer HOUSTON & MUNICH--( BUSINESS WIRE )--InGeneron, Inc., a regenerative medicine and biotechnology company, announced today that … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Mergers & acquisitions Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China June 24, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide e … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
New Study Reports Broad Applicability of InGeneron’s Regenerative Cell Therapy System Across Patient Groups - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio New Study Reports Broad Applicability of InGeneron’s Regenerative Cell Therapy System Across Patient Groups January 6, 2023 | 4 min read Twitter LinkedIn Facebook Email Print InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a newly released study, titled “The compositio … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
InGeneron Publishes Overview on Current State and Potential of Regenerative Cell Therapy in Orthopedics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio InGeneron Publishes Overview on Current State and Potential of Regenerative Cell Therapy in Orthopedics January 24, 2022 | 4 min read Twitter LinkedIn Facebook Email Print InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a succinct scientific review of regenerative cell … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
InGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tren … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio InGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial November 3, 2023 | 6 min read Twitter LinkedIn Facebook Email Print InGeneron, Inc., a clinical stage biotechnology company, announces the publication of a Phase III 480-patient clinical trial sp … xperience significant pain relief and improvement of joint function by repeated application of the therapy rather than a single application. Conversely, patients with mild pain may not show dramatic improvements simply because their baseline pain is already low. Moderate pain patients stand to show a more pronounced response, thus providing a clearer measure of treatment efficacy. Real-world Applicability : Targeting the subgroup of patients with moderate pain scores for anal … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
InGeneron Announces Critical In-Depth Analysis of the Results from a Recently Published 480-Patient Phase III Knee Osteoarthritis Trial - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development InGeneron Announces Critical In-Depth Analysis of the Results from a Recently Published 480-Patient Phase III Knee Osteoarthritis Trial November 21, 2023 | 4 min read Twitter LinkedIn Facebook Email Print InGeneron, Inc., a clinical stage biotechnology company, announces a critical in … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst " href="https://www.biospace.com/deals/lilly-astellas-circle-sangamo-assets-as-biotech-files-for-bankruptcy" > Bankruptcy Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy June 23, 2026 · 3 min read · Gabrie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
InGeneron Announces Presentation Of Results From Investigator Initiated Case Series Of Its Regenerative Cell Therapy In Chronic Back Pain At IFATS - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Ma … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio InGeneron Announces Presentation Of Results From Investigator Initiated Case Series Of Its Regenerative Cell Therapy In Chronic Back Pain At IFATS November 21, 2016 | 3 min read Twitter LinkedIn Facebook Email Print HOUSTON & MUNICH--( BUSINESS WIRE )--InGeneron, Inc., a regenerative medicine and biote … RT System and proprietary Matrase™ enzymatic reagent for immediate therapeutic application within 60 minutes, positioning the system for easy integration with many standard operating room procedures. The abstracts and presentations are available on the InGeneron website through this link . About InGeneron InGeneron is elevating the field of regenerative medicine by translating robust science into proven patient benefit. Our purpose is to set new therapeutic standards by enab … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bus … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body November 23, 2021 | 5 min read Twitter LinkedIn Facebook Email Print InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, announced the publication of t … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Privacy Policy - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Privacy Policy Home / Privacy Policy Privacy Policy Data Controller The data controller responsible for processing personal data on this website within the meaning of the General Data Protection Regulation (GDPR) is: InGeneron GmbH Sonnenstraße 24-26 8
Press Releases Archives - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Press Releases Home / Press Releases Search for press releases Press Releases Feb 4, 2026 InGeneron, Inc. Announces EU Quality Management System Certificate Under MDR Regulation (EU) 2017/745 for Medical Devices Press Releases Jul 23, 2025 InG
Physician Portal - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Physical Portal Our comprehensive resources are designed to support healthcare professionals by providing up-to-date, evidence-based content that enhances patient care and outcomes. Home / Physician Portal This content is password-protected. To view
Careers - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN DE About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Careers Interested in a career on the cutting edge of medical innovation? Search our job openings and apply to join our fast-growing team of bold innovators. Home / Careers We’re a workplace that draws ambitious people who are driven to get better every da
Careers - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN DE About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Careers Interested in a career on the cutting edge of medical innovation? Search our job openings and apply to join our fast-growing team of bold innovators. Home / Careers We’re a workplace that draws ambitious people who are driven to get better every da
Clinical Trials - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Clinical Trials All InGeneron clinical trials are fully enrolled. Home / Clinical Trials Clinical Trials Enrollment Status Rotator Cuff Tendinopathy (Full) Facet Joint Syndrome (Full) Wrist Osteoarthritis (Full) Have any Questions ? Important In the U
InGeneron Careers, Perks + Culture | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies InGeneron Teams InGeneron Save Saved Houston 24 Total Employees Year Founded: 2006 View Website Overview Jobs Offices Is This Your Company? Claim Profile Healthtech Biotech InGeneron enables novel, safe, and evidence-based therapies that unlock the healing potential of each patient's own regenerative cells. InGeneron Offices OnSite Workspace Employees work from physical offices. Typical time on-site: None Houston, T
Careers - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN DE About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Careers Interested in a career on the cutting edge of medical innovation? Search our job openings and apply to join our fast-growing team of bold innovators. Home / Careers We’re a workplace that draws ambitious people who are driven to get better every da
InGeneron Jobs + Careers | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies InGeneron Teams InGeneron Save Saved Houston 24 Total Employees Year Founded: 2006 View Website Overview Jobs Offices Is This Your Company? Claim Profile Jobs at InGeneron Let Your Resume Do The Work Upload your resume to be matched with jobs you're a great fit for. Upload Resume Success! We'll use this to further personalize your experience. No jobs to discover at this time. back to overview Jobs at similar companies View All Cam
%PDF-1.7 %���� 6954 0 obj >stream h����,�q���9&�m��$`pb6 �% A�gy# ���'���Sl��m5g,��\v��a�l�X$,��v+j����)���H�[��&9x|�Zoͷ[N5�'I�\\���rk�d�7M�$~,7��rP����M�yP՛z ����rPjAւ�oֳO�Z�(M%�L�^�g`U�Y�rs鹔����T��%����j�f7�,����$�v�9�Tz���+��tk��E- om�A%�[E��M�g/�kP�Io����Mz�)/ro�Ւm���*��h��J��[�W���o� �puk��Ѵ��K�Q�w����%�vL)�J ��=A�Y��)�4�=A/�[�N饕���K���Kk{i���|O�鶗Xz�h������:����X���n���=�v�^�������)���Dcd���nϺ��Z{i���zi%���V��Z/�Ꞡ����Z/����(Ͷ��0���'�����D �=A�f����=����~x~���v����nޢ�:��݇�o?�_��� ����w���Xܞ�����߿���{�O�����' ?|�Ş�O����ϣ�_|�����>~��ۧO����� ���w�����g��_��? … V�_�r1W;dzs��R���c�n6�g�)��ʀ7 ��:��Ĕ���s@�;��ё�h[9t��J� ���!;`&\.$51���'�״rfp�g��r��,��j�s��0P��%��0|W_k$�!"�ڼ�u�ܨ�����"?��רi��Wz\R�7��������*�7�05E?�^U�$�rF��P���\Fo�+y� 8��i �����͒[�����w� ����*1���.$ ��Q��p�p|'����`�˅t�^�� 5�x�QR����V�:ns��u�M�"��榾���i�R�;�,�u� k �ƶ�v͎��Ζ��"��ї�'n���]���t}�������{0��]���_��� �M[O�qJ�+�^���խu i��ל���iu��)�>��m�^����?���ѪR� \ �0�d��ɕ��#_=z� wE��-m���� � �I��|c����Q������5e���3�15�5�w8� j�����D��wK … �Zn/��5o���;��U�9_7�l:/N:fz3��ܭa^� >stream Microsoft® Word for Microsoft 365 application/pdf Jennifer Hollands Microsoft® Word for Microsoft 365 2021-09-23T17:37:50+10:00 2021-09-23T17:41:41+10:00 2021-09-23T17:41:41+10:00 uuid:BC8E6918-2CC2-4B86-8EFA-95FB3FD698FC uuid:892fe1b2-0388-4bef-8a2e-309521614235 endstream endobj 6926 0 obj > endobj 6937 0 obj >stream H��W�r�8}�W�ќ*��`ej��8;�T�Mby�aj 8�|�u$�D����۸4�u��b��it�9g���ᶙ��� ��۶��/nȯg����������iA��/��Ś��Կ���òi VK��O … 4!w��eےOUm;��Z�3KfQ��X �7����\U��������a8��j�����Ʒ��M�j�k� �6��Mn =G@���RFp�d,��$������ �d��}o�鞼s|={s��f�,�|�$��X� �3*^�J�9T��rT��?�c'ş�5ԩ:���U:kuk�E�v����_�����[�w��e�K� Mm��ZN�e,I0?�o>��ge��q���'�q�/��Zj V���w����H����ۘ��S|1��.�0W���Xnn�8`G��F���q���W�9� f����wVI�_���g��/�o�o��_���҉]�7n�>Ppv�sϙ�yd��*t%u�/�����x#9�]VT��E�W����R{�}6_7��� d��g��.��m,��k��A��+p�A�>�ڿ8�EL�J���������~��x(g� S���S��� m�o+�+�S�O �r����\��Y�B &�*��c��B�7�^��v7 �2WR�kw��
InGeneron - aVenture Company Research Home Research Loading aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions. aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcas
%PDF-1.4 %���� 1 0 obj /Creator /Keywords /Producer /Subject (lLVJ) /Title /CreationDate /ModDate >> endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 5 0 obj > stream (��Y��i3�^ ����Ӊ��&:���Dq�GR�M���u v�A%#�y�dܵ��DF�@k;���~���+h� }7m]��ɼ�M'��ܡ���x-�H���x��l�p ��������l1RB�Q��bR^f`Yk��#��D �:էr����,�ϕ�@��2���%yu����9�C��"�)vn �(�^�k�%�D�����k��������|�+x��O�1�|6�� x�h��KF��P�\�k��G��B�>m�i&�)�,����-G� ��+N�b����%S��/&b( "��d(h ߯��R>e��ԋcN7�C� ԅr3������E5��"�ݐ�$��'�J��KC�]�&����7����%VH�?7�ר8g Es�_&���tC y��IZ%��8#ەR��I Bk�C ���L>Ƥu
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
%PDF-1.6 %���� 2849 0 obj > endobj 2873 0 obj >/Filter/FlateDecode/ID[ ]/Index[2849 65]/Info 2848 0 R/Length 115/Prev 1541634/Root 2850 0 R/Size 2914/Type/XRef/W[1 3 1]>>stream h�bbd```b``Q��@$#�d���`�#�dLP�|@d��H�;�Į �� Dz���@� � ��/X�,����� $���9�{X=�0'�3|�`�� endstream endobj startxref 0 %%EOF 2913 0 obj >stream hQ�+a��cfv�2�ΎZ�� l����"�#�Jk͒mS[ l�J �z}�=Im�)�r�ۺ�$6������;����zz���������p@� LBƯ��!�pf@��w�Ǥ������L���������u�t. ��� �� �94�W�#2� �z�Y��!dM�bi���fO G�ηa��ڪ�nMk �LG���aM��\2^7A;&hP�N��ѩ�dtJ� $nr���ڵWY�R\��:M*R�Va{ԌR�RPJlw�cԬ��+kE�°���+0�� … ����� � `CA�"�eɰg�pRN1�E�dM�씜IN�` 4�]�ևx�և� ��ȭ��4ͭs��6��u�u}ѴW�uS��.� �RʽrFP���hNP���AnFP��`m�,3�j�8�A wqt����Y�l��H��0 Y�� �2�x�e�O�A�ŏ��W7; ���w;+���ˣ?W�ɮ��uֵ����� ��;˓�����O����Aq�: >stream h��X�n�6��@� ���������>}�IJ��v�Pe���� �ֶB�p?���tΜ�Q �c x ��O&%�� �c#����@�3.6�A+`��^��`Vp`w f��HƓ���g��5AYL�^ g��M�LR��MFe��р� b ���7@H,�4��a$àGD�be�"I*�āF��Z��d$�� 8Ki�Z����)�R� $�Lj�F֨�7���? 8�"[�\���� �Y��^�����% G%44N �qS �ҩ}�?���� … 13ba5f-3a7b-4cc9-a970-a05f8cd58e5d uuid:2fdd5bd0-c355-6b40-8860-0a2dab6e59c5 16 application/pdf National Instruments Adobe PDF Library 10.0 D:20130625203922 endstream endobj 119 0 obj >stream hޜѿ� �W�7�;������4nơ��qQ�����GM]�G~ᮜđ%Nd^=��s�v���� ��!�$��1������fs:�wY�ԃ)Aj�B q{�}]G� �� S+�. �*�r�n�t��H�Us��"���{\���ፘ����h >stream h�L�M �@��2;ua�?�A� �Z� �����u\��S jw/G�À�����d��i��Ov�Cc�{38� ���'{^�ע�F��N�!!��V$.����f-� +iإ8��q�k�� I9^�����@�܅�]�X�YRX�
%PDF-1.4 %���� 419 0 obj > endobj xref 419 105 0000000016 00000 n 0000003080 00000 n 0000003227 00000 n 0000003939 00000 n 0000004122 00000 n 0000004159 00000 n 0000004273 00000 n 0000004385 00000 n 0000005135 00000 n 0000005793 00000 n 0000006432 00000 n 0000007061 00000 n 0000007603 00000 n 0000007880 00000 n 0000008462 00000 n 0000008737 00000 n 0000008926 00000 n 0000009983 00000 n 0000010569 00000 n 0000010596 00000 n 0000010741 00000 n 0000011949 00000 n 0000013138 00000 n 0000013649 00000 n 0000013829 00000 n 0000015135 00000 n 0000015635 00000 n 0000016647 00000 n 0000017198 00000 n 00 … 445878788a7 xmp.did:b07a5dde-032d-4f92-a6e7-aa9f9e8562c5 default converted from application/x-indesign to application/pdf Adobe InDesign CC 2015 (Macintosh) / 2017-03-20T13:26:40-05:00 application/pdf Adobe PDF Library 15.0 False endstream endobj 56 0 obj > endobj xref 0 419 0000000000 65535 f 0000623263 00000 n 0000623870 00000 n 0000635967 00000 n 0000636089 00000 n 0000636122 00000 n 0000636198 00000 n 0000647170 00000 n 0000647491 00000 n 0000647551 00000 n 0000647663 000
InGeneron Funding: How Much Did They Raise & Key Investors Products Product ZoomInfo Copilot AI sales agent GTM Workspace AI workspace for smarter GTM GTM Studio Build and run GTM workflows triggered by buying signals ZoomInfo MCP Connect your AI to verified B2B data Sales Company and contact database Marketing Actionable ABM platform Talent Source the best and brightest Operations Lead routing and data quality Data as a Service ZoomInfo data for your GTM systems Platform Cloud partners Ready, set, integrate Platform overview Connect industry-leading data across your entire tech stack Mark … a patient's own regenerative cells, processed at the point of care for same-day application. The company is currently concentrating on orthopedic conditions, actively conducting clinical trials to validate its technology as a disease-modifying intervention. This strategic approach aims to unlock the inherent healing potential within each patient, offering a new paradigm in regenerative medicine. How much funding has InGeneron raised? InGeneron has raised a total of $33.4M acr
%PDF-1.4 %���� 1 0 obj > endobj 2 0 obj >stream 2022-01-14T05:27:10 Adobe InDesign 15.0 (Windows) 2022-01-21T10:30:38+01:00 2022-01-21T10:30:38+01:00 Adobe PDF Library 15.0; modified using iText® 5.3.5 ©2000-2012 1T3XT BVBA (SPRINGER SBM; licensed version) Adipose-derived regenerative cells;ADRCs;Adipose-derived stem cells;ADSCs;Bone regeneration;Cartilage regeneration;Efficacy;Point of care treatment;Stem cell;Tendon healing without scar formation;Tendon regeneration;vaPS cells False application/pdf https://doi.org/10.1186/s13018-022-02918-8 BioMed Central Journal of Orthopaedic Surgery and R … 7f49-b7c4-ebe80410a703 uuid:463043d3-d1c3-4557-aab0-86160f4b35ee converted from application/pdf to application/vnd.adobe.photoshop derived converted from application/vnd.adobe.photoshop to image/tiff uuid:ca539f0e-0e0e-4415-9de4-cb75f0168c58 uuid:463043d3-d1c3-4557-aab0-86160f4b35ee image/tiff Christoph Schmitz Adobe PDF Library 10.0 D:20220106041848 endstream endobj 79 0 obj >stream ����Adobed��� … Oregon_LDO_Book_Sinistral.ttf Cyan Magenta Yellow Black Default Swatch Group 0 application/postscript Shailaja P. BMC_logo4_new_19-2-18.eps xmp.did:02FAC5D69517E811A4BBCDCA7D760AD9 xmp.iid:02FAC5D69517E811A4BBCDCA7D760AD9 xmp.did:02FAC5D69517E811A4BBCDCA7D760AD9 converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.ill … from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:02FAC5D69517E811A4BBCDCA7D760AD9 2018-02-22T12:36:39+05:30 Adobe Illustrator CS6 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converte … from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator endstream endobj 356 0 obj > endobj 357 0 obj >/ProcSet[/PDF/Text]/Font >/Properties >>> endobj 337 0 obj >stream x��Y�n ����D�Q�f�/��@R ��D�yH�`�;$'؛w������&9U�3�KR�Dz ���VU��=/g��gw՜�~���М��ߕ�bv��ٜ~
Series D Financing Extended to $43M --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us News Home / News / InGeneron Extends Series D Financing to $43 Million to Bring Regenerative Cell Therapy into the Clinic June 11, 2019 Category: News InGeneron Extends Series D Financing to $43 Million to Bring Regenerative Cell Therapy into
Technology - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN DE About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Technology Platform In the US, InGeneron’s Transpose Ultra ® platform is for investigational use only. We offer a portfolio of our technology for the preparation and administration of adipose-derived regenerative cells. Home / Technology Processing Unit
Angelo Moesslang InGeneron GmbH [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Roche and Nurix: up to $2.3b Agreement for BTK Degrader AMD Commits up to £2b to Accelerate AI in UK DaltonTx Launches Platform and Partners w … to Biosciences and DaltonTx: AI-Driven Collaboration » More News! » Submit your News! Upcoming Events UBS Life Sciences Conference 2026 London Metabolomics 2026 Buenos Aires BIO 2026 San Diego (BIO International Convention) TD Cowen’s Tools/Dx Revolution Conference 2026 Dana Point Truist Securities Healthcare Disruptors & Digital Health Conference 2026 New York LSI Asia ’26 Emerging MedTech Summit 2026 Singapore Longevity Summit Dublin 2026 European Spatial Comput … f America Global Healthcare Conference London 2026 » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Camil … n Bulling Joins ProBioGen as Chief Operating Officer » More News! » Submit your News! Financings & Acquisitions Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lilly to Acquire LimmaTech Biologics for up to $780m in Cash InSphero Acquires PhenoVista Biosciences to Expand in US Lauxera Capita … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m Metis TechBio: $270m IPO at Hong Kong Stock Exchange NanoStruct Closes €2.6m Seed Round Led by HTGF et al. Roche to Acquire PathAI for up to $1.05b » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agree
InGeneron Announces Changes In Management Team - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business InGeneron Announces Changes In Management Team February 15, 2017 | 2 min read Twitter LinkedIn Facebook Email Print HOUSTON--( BUSINESS WIRE )--InGeneron, Inc., a regenerative medicine and cell therapy company, today announced changes in its leadership team. Michael Coleman, PhD, has stepped … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Mergers & acquisitions Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China June 24, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide e … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
InGeneron CEO Steps Down, Hunt for New Leader Begins - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business InGeneron CEO Steps Down, Hunt for New Leader Begins February 15, 2017 | 2 min read Twitter LinkedIn Facebook Email Print InGeneron Announces Changes in Management Team February 14, 2017 06:00 PM Eastern Standard Time HOUSTON--( BUSINESS WIRE )--InGeneron, Inc., a regenerative medicine and ce … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Mergers & acquisitions Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China June 24, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide e … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
%PDF-1.4 %���� 1337 0 obj > endobj xref 1337 66 0000000016 00000 n 0000002473 00000 n 0000002633 00000 n 0000003235 00000 n 0000003264 00000 n 0000003405 00000 n 0000003551 00000 n 0000003817 00000 n 0000004218 00000 n 0000004641 00000 n 0000005358 00000 n 0000005387 00000 n 0000005989 00000 n 0000006428 00000 n 0000006494 00000 n 0000006607 00000 n 0000006722 00000 n 0000006983 00000 n 0000007394 00000 n 0000007662 00000 n 0000008298 00000 n 0000009744 00000 n 0000010186 00000 n 0000010457 00000 n 0000010927 00000 n 0000012208 00000 n 0000012623 00000 n 0000013044 00000 n 0000013312 00000 n 0 … 2d-602015dfaa1d xmp.did:47CE3A52EDBBE0118999B11FF1968BE5 default converted from application/x-indesign to application/pdf Adobe InDesign CC 2017 (Windows) / 2021-10-13T14:54:32+08:00 application/pdf Adobe PDF Library 15.0 False endstream endobj 64 0 obj > endobj xref 0 1337 0000000000 65535 f 0000103334 00000 n 0000103797 00000 n 0000111070 00000 n 0000112411 00000 n 0000113752 00000 n 0000119846 00000 n 0000308720 00000 n 0000308780 00000 n 0000309212 00000 n 0000316448 0000
Who Attended in 2022 - The MedTech Conference Skip to content About Event Updates Why Attend Travel and Housing #MTC25 Highlights Blog FAQs Program Program Overview Call for Sessions Corporate Reverse Pitch Presentations Affiliated Events Schedule at a Glance 2025 Schedule Attendees Who Attends AdvaMed Members Start-ups & Early Stage Companies Service Providers & Suppliers Hospital & Government Established Manufacturers Students Early Career Attendee List Company List International Investors Networking Exhibit & Sponsor Sponsorship Opportunities Sponsors 2026 Floor Plan Medte … pany: CoSec Consulting Title: VP - North America Company: Coulter Translational Fund Title: Associate Director Company: Cowin Capital Title: Investment Director Company: CPAFFC Title: Director, U.S. Division, Department of American & Oceanian Affairs Company: Credit Suisse Title: Managing Director Company: CroiValve Title: VP Business Development Company: Crowell & Moring LLP Title: Senior Policy Director Company: CSA Service Solutions Title: Director, Strategy & Bus Dev Comp … or Company: GPEC Title: Senior Vice President of Strategy and Research Company: Grant Thornton LLP Title: Healthcare and Life Sciences Industry Leader Company: GREATER MSP Title: Director, Business Investment Company: Greater Zurich Area Title: Senior Advisor Americas Company: Greenberg Traurig Title: Chair of Global Litigation Company: Greenberg Traurig, LLP Title: Shareholder Company: Grünenthal GmbH Title: International Project Lead Company: GT Medical Technologies, Inc. T … y: Sysmex Corporation Title: Product Development Engineer Company: TEDCO Title: Award Manager Company: Teleflex Medical Title: Director, Corporate Development (M&A) Company: Temple Health and Bioscience Distric Title: PR Account Coordinator Company: Temple University Title: Assistant Professor, Thoracic Medicine and Surgery Company: Terumo Americas Holding Title: Director of Quality Systems Compliance Company: Terumo Medical Corporation Title: Senior Resercher Company: Texas … osts What Winning Pitch & Pour Meant for Cohesys — And Why Start-Ups Should Apply June 10, 2026 Welcome Home Medtech. Why Boston is the Perfect Host for The MedTech Conference June 8, 2026 Why Global Medtech Companies Are Making #MTC26 A Priority May 8, 2026 MEDTECH MOVES US Instagram Youtube Linkedin-in #MTC26 Attend Register Why Attend Netw
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Sponsors & Exhibitors – European Plastic Surgery Research Council LOGIN HERE APPLY FOR MEMBERSHIP ONLINE CONTACT US VIEW CART European Plastic Surgery Research Council Home About Executive Committee Membership Types of Membership Member Roster Online Account Endowment Fund Cruise Fellowship Rules and Eligibility Criteria Online Application Our Winners Congress President’s Message Captain’s Message Program and Abstracts Pre-Congress Instructional Course Abstract submission Faculty and chairs Registration General Information Social Events Accommodation Awards Sponsors & Exhibitors … Committee Membership Types of Membership Member Roster Online Account Endowment Fund Cruise Fellowship Rules and Eligibility Criteria Online Application Our Winners Congress President’s Message Captain’s Message Program and Abstracts Pre-Congress Instructional Course Abstract submission Faculty and chairs Registration General Information Social Events Accommodation Awards Sponsors & Exhibitors Past Meetings Download & Links Endorsed Meetings Disclaimer Sponsors &
Encouraging Results from 480-Patient Knee Osteoarthritis Trial --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us News Home / News / InGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial November 3, 2023 Category: Press Releases InGeneron Announces Encouraging Results fro … xperience significant pain relief and improvement of joint function by repeated application of the therapy rather than a single application. Conversely, patients with mild pain may not show dramatic improvements simply because their baseline pain is already low. Moderate pain patients stand to show a more pronounced response, thus providing a clearer measure of treatment efficacy. Real-world Applicability : Targeting the subgroup of patients with moderate pain scores for anal
10-K 1 cytx-10k_20181231.htm 10-K cytx-10k_20181231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from            to            Commission file number 001-34375 … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes   ☒     No   ☐ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in … ial is expected in the first half of 2019. In October 2018, Cytori submitted an application to the Evaluation and Licensing Division of the Japan Pharmaceuticals and Medical Devices Agency (PMDA) through the SAKIGAKE designation system to potentially obtain a prioritized and shortened review, 6 months instead of 12 months, of the future ECCI-50 registration application. Cytori expects to obtain the result of the designation decision in the first half of 2019. … hese data to serve as the basis for our submission of a marketing authorization application for ATI-0918 to the EMA. In June 2017, Cytori received confirmation of eligibility for submission of an application for a Union Authorization for the medicinal product, ATI-0918, from the EMA Committee for Medicinal Products for 4 Human Use (CHMP). In December 2018, Cytori received approval from the EMA CHMP Name Review Group (NRG) for Doxorubicin Hydrochloride Cytori … t Lipodox® to serve as the basis for submission of an abbreviated new drug application, or ANDA, for U.S. FDA approval. We currently anticipate that any U.S. bioequivalence trial for ATI- 0918 would be funded by a development partner or licensee. ATI-1123 is a novel liposomal formulation of docetaxel. Generic forms of docetaxel ar
Top 20 Cell seeding companies - Discovery|PatSnap Log In Free Trial Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka! Start Your Search 352 results about Cell seeding companies See how new Discovery Search works for you Find the fast-growing company Growth Fast to Slow Sort by: Most relevant Most relevant Growth Fast to Slow Seeding simply means to spread a defined amount (volume or cell number) of a cell suspension into a new flask or onto a plate etc. When you work with adherent cell cultures you have to trypsinize them first to get a cell suspension.
| BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzheimer's dise … ve Biologics Inc. and it moved its business operations to Houston following the award of a $20 million grant from the Cancer Prevention and Research Institute of Texas, which is supporting the development of drug candidate Aravive-S6 as a potential treatment for acute myelogenous leukemia and solid tumors, including ovarian, pancreatic and breast cancers. Read More Novartis nabs Selexys for potential $665M, gains phase II agent for SCD pain crises Less than two weeks before t
Eckhard Alt - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 Early life 2 Career 3 Philanthropic work 4 Distinctions and honors 5 Excerpt of publications 6 References Toggle the table of contents Eckhard Alt 2 languages مصرى Deutsch Edit links Article Talk English Read … re two institutions supported by him. Distinctions and honors [ edit ] Research prize of the European Society for Cardiovascular Surgery 1998 [ 11 ] Research prize of the Erasmus Universität Rotterdam als Best Cardiovascular Researcher 1997 [ citation needed ] Named one of the leading cardiologists and specialists cardiac arrhythmia in the publications: Die besten 1.000 Ärzte (The best 1000 doctors) und Die besten 100 Kardiologen Deutschlands (The best 100 car … ary-Artery Stents in Acute Biodegradable coating with inhibitory properties for application to biocompatible materials Vascular and endoluminal stents with improved coatings Flexible implantable stent with composite design References [ edit ] ^ "The Sanford Project selects new leader" . Sanford Health . Retrieved 2016-11-16 . ^ "Tulane University - Heart and Vascular Institute" . Archived from the original on 2013-08-01 . Retrieved 2016-04-15 . ^ Sanford Health Newsroom ^ "M. … the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization. Privacy policy About Wikipedia Disclaimers Contact Wikipedia Legal & safety contacts Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents Eckhard Alt 2 languages
Regenerative Medicine Archives - Page 6 of 7 - Drug Delivery Business Skip to primary navigation Skip to main content Skip to primary sidebar Skip to footer Advertise Subscribe Drug Delivery Business Search this website Clinical Trials Research & Development Drug-Device Combinations FDA Pharmaceuticals Policy Reports Diabetes Technology Innovations Special Report Continuous Glucose Monitoring (CGM) Market Report Regenerative Medicine NuTech Medical acquired by Organogenesis March 28, 2017 By Sarah Faulkner Organogenesis said today that it acquired NuTech Medical for an undisclosed price. T … ruary 28, 2017 By Sarah Faulkner Johns Hopkins, the Maryland Stem Cell Research Fund and BioCardia (NSDQ:BCDA) said today that the 1st patient has been treated in a pivotal Phase III trial of the CardiAmp cell-based therapy for the treatment of ischemic heart failure. The investigational therapy was designed to deliver a dose of a patient’s own bone marrow cells directly […] Filed Under: Cardiovascular , Clinical Trials , Featured , Regenerative Medicine , Wall S
Lone Star Bio articles and careers information on BioSpace Skip to main content Skip to main menu Skip to user menu Jobseeker Sign in News Drug Development FDA Drug Delivery Deals Business Policy Cell and Gene Therapy Weight Loss Rare Disease Cancer Job Trends Artificial Intelligence NextGen: Top Start Ups To Watch Podcasts Reports Webinars Press Releases All News & Releases Insights Jobs Search Jobs Job Alerts Jobseeker Sign In Career Advice Companies Hotbeds More Best Places to Work Employer Resources Post Jobs Talent Solutions Advertise Submit a Press Release Subscribe Subscribe Search Jobs … icy More Employer Login Employer Resources Post Jobs Talent Solutions Advertise Submit a Press Release RSS Feeds Facebook This will open in a new window Twitter This will open in a new window LinkedIn This will open in a new window Instagram This will open in a new window © 1985 - 2026 BioSpace.com. All rights reserved. Powered by Madgex Job Board Software
InGeneron GmbH - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Roche and Nurix: up to $2.3b Agreement for BTK Degrader AMD Commits up to £2b to Accelerate AI in UK DaltonTx Launches Platform and Partners with Sygnature O … to Biosciences and DaltonTx: AI-Driven Collaboration » More News! » Submit your News! Upcoming Events UBS Life Sciences Conference 2026 London Metabolomics 2026 Buenos Aires BIO 2026 San Diego (BIO International Convention) TD Cowen’s Tools/Dx Revolution Conference 2026 Dana Point Truist Securities Healthcare Disruptors & Digital Health Conference 2026 New York LSI Asia ’26 Emerging MedTech Summit 2026 Singapore Longevity Summit Dublin 2026 European Spatial Comput … f America Global Healthcare Conference London 2026 » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Camil … n Bulling Joins ProBioGen as Chief Operating Officer » More News! » Submit your News! Financings & Acquisitions Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lilly to Acquire LimmaTech Biologics for up to $780m in Cash InSphero Acquires PhenoVista Biosciences to Expand in US Lauxera Capita … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m Metis TechBio: $270m IPO at Hong Kong Stock Exchange NanoStruct Closes €2.6m Seed Round Led by HTGF et al. Roche to Acquire PathAI for up to $1.05b » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agree
InGeneron Stock Price, Funding, Valuation, Revenue & Financial Statements Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Partners Turb
InGeneron — Grokipedia Search ⌘K Suggest Edit Sign in Sign in Overview Company Profile Mission and Operations History Founding and Early Years Expansion and Key Events Technology and Products Core Technology Transpose RT System Accessories Human Applications Veterinary Applications Applications Human Therapeutics Veterinary Uses Regulatory Status Approvals and Certifications Manufacturing Compliance Recent Developments Clinical Trials and Studies Funding and Innovations References Fact-checked by Grok 5 months ago InGeneron Ara Eve Leo Sal 1x InGeneron Inc. is a clinical-stage biotechnology co … r the company's cell therapy platform, enabling rapid processing and autologous application in regenerative treatments. [12] Expansion and Key Events In 2010, InGeneron expanded its international presence by establishing its wholly owned subsidiary, InGeneron GmbH, in Munich, Germany, to serve as the company's European headquarters and facilitate operations across the continent. [4] A notable application of InGeneron's technology occurred in 2012, when it was used to treat a … dicine through integrated lab-supported evidence for stem cell preservation and application. [4] [14] Throughout this period of growth, InGeneron collaborated with academic institutions on research, resulting in more than 100 peer-reviewed publications that validated its adipose-derived regenerative cell technologies for orthopedic and wound healing indications. These partnerships underscored the company's commitment to evidence-based expansion in regenerative medicine. [15] … ation. [12] The semi-automated, workflow-integrated design streamlines clinical application by automating digestion, separation, and concentration steps, ensuring reproducibility and compliance with minimal manipulation guidelines for homologous use. [11] [12] This approach, implemented in systems like the Transpose RT, differentiates InGeneron's platform by prioritizing efficiency and safety in regenerative cell processing. [12] Transpose RT System The Transpose RT System is … overy in high-value athletes. [4] A prominent example of InGeneron's veterinary application occurred in 2012 at the Houston Zoo, where the company processed stem cells from the abdominal fat of Pandu, a 286-pound Malayan tiger suffering from arthritis and bone chips in his right elbow. Following arthroscopic surgery to remove the fragments, the i
InGeneron Completes Strategic Financing --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us News Home / News / InGeneron Completes Strategic Financing from Sanford Health to Advance Regenerative Cell Therapies March 6, 2017 Category: News InGeneron Completes Strategic Financing from Sanford Health to Advance Regenerative Cell The … apies available to clinical practice and to establish a leading position in the application of adipose-derived regenerative cells.” Earlier this year, Sanford began enrolling participants in the FDA-approved Safety and Efficacy of Adult Adipose-Derived Stem Cell Injections into Partial Thickness Rotator Cuff Tears clinical trial. The trial uses stromal vascular fraction, a mixture of cells and nutrients isolated from a patient’s own body that contain adipose-derived stem cell … ickness rotator cuff tears. Sanford scientists and clinicians are exploring the application of this type of stem cells for other conditions. Kelby Krabbenhoft, President and CEO of Sanford Health, notes that InGeneron’s approach can help meet a medical need in key orthopedics and wound healing. “Our active collaboration enabled us to be among the first U.S. health care providers to study adipose stem cell therapy in clinical trial,” Krabbenhoft said. “The investment and exper … erived regenerative cells from the patient’s own body for immediate therapeutic application at point of care. InGeneron has an active collaboration with Sanford Health to conduct its clinical trials in rotator cuff tears and venous ulcers at different sites in the Sanford Health network. These studies aim to investigate the safety and efficacy of using autologous adipose-derived regenerative cells in patients compared to current standard of care treatments. With the aim of re
%PDF-1.6 %���� 1 0 obj >stream application/pdf Fibroblasts share mesenchymal phenotypes with stem cells, but lack their differentiation and colony-forming potential PDFlib PLOP 2.0.0p6 (SunOS)/Acrobat Distiller 7.0.5 for Macintosh; modified using iText 4.2.0 by 1T3XT 10.1042/BC20100117 10.1111/boc.2011.103.issue-4 2 2011-03-13T08:49:13+05:30 LaTeX with hyperref package 2022-06-08T05:55:28-07:00 2022-06-08T05:55:28-07:00 uuid:2e295322-0638-4264-b896-2dbf7a2f353c uuid:afb7831f-2013-4314-b33f-9e4044d9a1e3 endstream endobj 4 0 obj >stream H�|Wێ����� [�H&�y�>�z�� $�� ��SV�˛v�'$;du'��\UT��[�U���
%PDF-1.5 %���� 82 0 obj > stream xڭisܶ���~+�za��_����I*�Mg�L��BZ�$��aY��}�{�ڵ�L�3&��}S��z�^>��d��"]�L�Y�3�i�Z���O/ p���*MX,�Ug,ɪ� ||��H)�̖�'�6 ����y�O����#�b\e �Y�FHʴ ��2�f�h�E���C�H�b���f[��h��-��#Ҟ����˅�֍n�~�����n ��|ݙ*��ͼ��Ϧl��C�����V6�P��۲(=i`R�ŭX�r��->�@�$\FlU�t5eq���D��(X�Is@I���� �Z��帎���G��i�ZϠCR~Y�x��L��xS���8 _P �%Y��*��Jέ��� [ E"��)Q$�ʟ��o/'�N$Sq�J"��*r�0����sO��-N:����'�^h%�,��H�\XyEvya���mu�hx�璒�T"Tb]e-� ��!Q��烹���z���A$x5��);F ����,~�kˮ7��G}�OR`Y�9Ru Q��T.��� `"�]]�� ��ÔYx3( �k>^ѱ�3�c>D��+�[rK�W�(���)�(����T����IP&��� !5��?���
Publication Archive - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Publications Explore the latest publications from InGeneron and our research partners. Home / Publication Search for publications Basic Science Jul 23, 2025 Regeneration of Biomechanically Functional Tendon Tissue Following Injection of Uncultured, A
Pipeline - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Pipeline Dedicated to developing regenerative cell therapies the right way, supported by clinical evidence and approved by the FDA. Home / Pipeline Pipeline Overview Indication Pre-Clinical Feasibility Study Pivotal Study Partial-thickness Rotator Cuff Tear
Technology - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN DE About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Technology Platform In the US, InGeneron’s Transpose Ultra ® platform is for investigational use only. We offer a portfolio of our technology for the preparation and administration of adipose-derived regenerative cells. Home / Technology Processing Unit
InGeneron, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 30 Jan 2026 InGeneron, Inc. Holding Company | 2006 | Texas, United States | 10-50 | ingeneron.com Holding Company | 2006 | Texas, United States | 10-50 | ingeneron.com Last update 30 Jan 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 9 Clinical Trials associated with InGeneron, Inc. NCT05400798 / Enrolling by invitation Not Applicable A Longitudinal, Multi-Center Safety Study of Autol … xperience significant pain relief and improvement of joint function by repeated application of the therapy rather than a single application. Conversely, patients with mild pain may not show dramatic improvements simply because their baseline pain is already low. Moderate pain patients stand to show a more pronounced response, thus providing a clearer measure of treatment efficacy. Real-world Applicability: Targeting the subgroup of patients with moderate pain scores for analy … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
InGeneron - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 History 2 Products Toggle Products subsection 2.1 Transpose RT System 2.2 Accessories 3 Regulatory 4 References Toggle the table of contents InGeneron Add languages Add links Article Talk English Read Edit View … the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization. Privacy policy About Wikipedia Disclaimers Contact Wikipedia Legal & safety contacts Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents InGeneron Add languages
Developing Cell-Based Therapies - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN DE About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Your browser does not support the video tag. Innovating Regenerative Medicine Leading Cell Therapy and Stem Cell Research for 16 Years. InGeneron is a biotechnology company developing cell-based therapies to redefine the standard of … quent washing and filtering steps prepare these cells for immediate therapeutic application. The entire procedure can be completed within a few hours in an outpatient facility. Get The Latest From InGeneron Press Releases Feb 4, 2026 InGeneron, Inc. Announces EU Quality Management System Certificate Under MDR Regulation (EU) 2017/745 for Medical Devices Press Releases Jul 23, 2025 InGeneron Publishes Landmark Study Demonstrating Structural Tendon Regeneration with Autologous
Christoph Schmitz MD, PhD - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Christoph Schmitz MD, PhD Advisory Medical Director Orthopedics at InGeneron, Inc. Christoph Schmitz MD, PhD 's Executive Work History Current Advisory Medical Director Orthopedics , Advisory Medical Director Orthopedics Equilar on 05/10/2026
Our Leaders - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN DE About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Leadership InGeneron is led by an international team of bold innovators creating the next generation of life changing therapeutics. Home / Leadership Management Team Board of Directors Management Team Eckhard Alt, MD, PhD CEO Eckhard Alt, MD, PhD CEO E … mong the “Best 12 Cardiologists in Germany.” Eckhard received the Hahn Research Award from the European Society of Thoracic Surgeons as well as the Ethica Award as Best Experimental Researcher from Erasmus University in Rotterdam. In 2009, he was named Entrepreneur of the Year in Munich and Innovator of the Year in Houston. In addition to being Executive Chairman of InGeneron, Inc., he is also chairman of the board of ISAR Klinikum in Munich, Germany. Fabian Alt, M.Sc. Chief … mong the “Best 12 Cardiologists in Germany.” Eckhard received the Hahn Research Award from the European Society of Thoracic Surgeons as well as the Ethica Award as Best Experimental Researcher from Erasmus University in Rotterdam. In 2009, he was named Entrepreneur of the Year in Munich and Innovator of the Year in Houston. In addition to being Executive Chairman of InGeneron, Inc., he is also chairman of the board of ISAR Klinikum in Munich, Germany. Klaus L. Keller Director … ing president of Medtronic’s CRM Business from 1991 to 1998. He manages his own fund of companies and serves on the advisory boards of Affinity Capital Management Fund III and IV and Sapient Capital Management Fund, in which he also invests. In addition, Bobby has served on the board of directors of several public companies, including MTS Systems Corporation and Urologix, Inc., and is currently a director of several private companies. Amber Langner, CPA, CHFP Director Amber L … h FDA, she developed a template that can be used for developing an original IDE application and has helped several institutions establish templates and infrastructure to successfully complete FDA-regulated clinical trials. Kathryn has served as a strategic advisor and board representative for several biotech companies from product development thr
Cell Therapy Results in Back Pain --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us News Home / News / InGeneron Announces Presentation of Results from Investigator Initiated Case Series of its Regenerative Cell Therapy in Chronic Back Pain at IFATS November 21, 2016 Category: News InGeneron Announces Presentation of Results fr … RT System and proprietary Matrase™ enzymatic reagent for immediate therapeutic application within 60 minutes, positioning the system for easy integration with many standard operating room procedures. The abstracts of both presentations can be found in the IFATS 2016 program . The presentations are available as PDF for the case series on chronic back pain preclinical study in a rat spinal fusion model. About the Transpose ® RT System and FDA approved clinical trials InGeneron
Partners - InGeneron --> About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us EN DE About Us Overview News Leadership Partners FAQs Science Cell Therapy Technology Pipeline Publications Patients Clinical Trials Physicians Careers Contact Us Partners Our partners span the globe but are all bound by the dedication to make healthcare better for patients. Learn about our great partners and how to get involved. Home / Partners Sanford Health In early 2017, InGeneron established a strategic partne